Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Replimune Securities Fraud Class Action Over FDA BLA Rejection

Analysis based on 139 articles · First reported Jul 29, 2026 · Last updated Sep 17, 2026

Sentiment
-20
Attention
2
Articles
139
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The litigation and the underlying FDA rejection of Replimune's BLA have severely damaged investor confidence in the company, with the stock reportedly losing the majority of its value across the April 2026 disclosures. Broader market impact is limited to the biotechnology sector, where the case reinforces regulatory and disclosure risk for single-asset clinical-stage developers, while the legal-services firms involved face no material market consequence.

biotechnology pharmaceuticals legal services

Multiple investor-rights law firms have filed securities fraud class actions against Replimune Group (NASDAQ: REPL) and certain of its officers, alleging violations of federal securities laws during the class period of October 20, 2025 to April 10, 2026. The complaints allege that Replimune failed to address study design concerns previously communicated by the United States — Food and Drug Administration regarding its Biologics License Application for RP1 in combination with nivolumab, and that it submitted data from an early unplanned analysis of the RP1-104 study covering only 40 patients, roughly 10 percent of the planned 400-patient enrollment. On April 10, 2026, the FDA published a Complete Response Letter rejecting the BLA, finding that the evidence did not meet evidentiary standards for regulatory approval and that previously communicated study design concerns were not addressed. Replimune shares reportedly fell 19.46 percent to $4.76 on April 10, 2026, and then a further 64.29 percent to $1.70 on April 13, 2026. Firms including Bronstein, Gewirtz & Grossman, LLC, Pomerantz LLP, Levi & Korsinsky, Glancy Prongay & Murray, Robbins LLP, and Schall Brown & Schwartz LLP are soliciting investors, with a lead plaintiff deadline of October 5, 2026. The FDA had earlier published briefing documents on July 28, 2026 questioning the response assessment used in the IGNYTE study, which reportedly drove a 38.01 percent share decline that day.

95 United States — Food and Drug Administration rejected biologics license application Replimune Group
90 Robbins LLP filed class action Replimune Group
85 Levi & Korsinsky filed securities class action Replimune Group
85 Pomerantz LLP filed class action Replimune Group
84 Replimune Group misled investors
84 Replimune Group misled investors
82 The Law Offices of Frank R. Cruz announced opportunity to lead lawsuit
80 Pomerantz LLP investigating claims Replimune Group
+ 26 more actions View on Dashboard
stock
Central defendant in the securities class actions and issuer of the rejected BLA; its shares reportedly collapsed from $4.76 to $1.70 in April 2026 and it faces ongoing litigation and regulatory setbacks.
Importance 100.0 Sentiment -85.0
govactor
Published the Complete Response Letter rejecting Replimune's BLA and earlier briefing documents questioning the IGNYTE study data, triggering the share decline that underpins the lawsuits.
Importance 70.0 Sentiment 0.0
per
Sushil Patel, CEO of Replimune, is named as an individual defendant in the class actions. Allegations of misleading statements and failure to disclose FDA concerns could lead to personal liability.
Importance 60.0 Sentiment -70.0
per
Emily G. Hilliard, CFO of Replimune, is named as an individual defendant. She is alleged to have certified misleading filings, potentially facing personal liability.
Importance 60.0 Sentiment -70.0
priv
One of the lead plaintiff firms repeatedly announcing the class action and urging Replimune investors to seek lead plaintiff appointment by the October 5, 2026 deadline.
Importance 40.0 Sentiment 0.0
priv
Filed and publicized the class action and is investigating claims on behalf of Replimune investors, detailing the FDA rejection timeline and share price declines.
Importance 35.0 Sentiment 0.0
per
Joseph E. Levi is a partner at Levi & Korsinsky and a contact for the class action. He represents investors in the lawsuit, but his personal impact is limited to his professional role.
Importance 30.0 Sentiment 10.0
priv
Announced the securities class action against Replimune and is soliciting affected shareholders to participate before the lead plaintiff deadline.
Importance 30.0 Sentiment 0.0
priv
Reminds investors of the October 5, 2026 lead plaintiff deadline in the class action and is soliciting participation.
Importance 30.0 Sentiment 0.0
priv
The Law Offices of Frank R. Cruz is soliciting investors with losses in Replimune to lead the ongoing securities fraud class action.
Importance 20.0 Sentiment 0.0
priv
Urges Replimune investors who suffered losses to contact the firm regarding the class action and potential recovery.
Importance 20.0 Sentiment 0.0
priv
Filed and publicized the class action against Replimune for alleged violations of the Securities Exchange Act of 1934.
Importance 20.0 Sentiment 0.0
stock
Its PD-1 inhibitor Opdivo was the combination partner in the rejected RP1 BLA; the rejection is a minor setback to one combination program within a large diversified portfolio.
Importance 15.0 Sentiment 0.0
priv
This firm announced the opportunity for investors to lead the class action, but is not prominently featured in the provided articles.
Importance 10.0 Sentiment 5.0
govactor
Referenced as the agency whose Rule 10b-5 and Exchange Act provisions underpin the securities fraud claims; no direct action by the agency is reported.
Importance 10.0 Sentiment 0.0
+ 10 more entities View on Dashboard
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Pomerantz LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as co-plaintiff with Pomerantz LLP in numerous securities class actio
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Glancy Prongay & Murray Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel with Glancy Prongay & Murray in various securities clas
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ The Law Offices of Frank R. Cruz Bronstein, Gewirtz & Grossman frequently acts as co-plaintiff with The Law Offices of Frank R. Cruz in securities class
Pomerantz LLP co-litigator ↔ Glancy Prongay & Murray Pomerantz LLP often works alongside Glancy Prongay & Murray as co-plaintiffs in securities fraud class actions, pursuing
+ 7 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.